Biopharma | May 05, 2026
Zydus Lifesciences subsidiary faces Rs 9 million GST demand notice
Company plans to appeal against CGST order related to alleged inadmissible input tax credit claims
Company plans to appeal against CGST order related to alleged inadmissible input tax credit claims
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
The company secured new accounts, including ACCESS-PVI trial sites, and aims to strengthen global commercialization efforts
Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
Week-long Fire Safety Week 2026 campaign focuses on strengthening fire prevention, preparedness, audits, and emergency response across hospitals and healthcare facilities
New facility at Pusa Road expands advanced diagnostic, theranostics, and treatment-planning capabilities across oncology, cardiology, neurology, and nephrology
On his visit to NIPER Mohali, union health minister vreviews biopharma research initiatives and calls for stronger industry collaboration and commercialization focus
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
New medical and wellness centre combines on-site care with telehealth to support industrial workforce and surrounding communities
Subscribe To Our Newsletter & Stay Updated
